Integrating a Predictive Clinical Biomarker Approach to Develop Oncology Therapeutics that Target Cell Division. We are a clinical-stage oncology therapeutics company, taking a PCMTM approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers. We believe that integrating a predictive clinical biomarker approach into our onvansertib clinical development program...
Integrating a Predictive Clinical Biomarker Approach to Develop Oncology Therapeutics that Target Cell Division. We are a clinical-stage oncology therapeutics company, taking a PCMTM approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers. We believe that integrating a predictive clinical biomarker approach into our onvansertib clinical development program may enable us to tailor treatment to specific sub-populations of patients who are most likely to respond and have a positive clinical impact.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.